Zika virus protection by a single low dose nucleoside modified mRNA vaccination by Pardi, Norbert et al.
Zika virus protection by a single low dose
nucleoside modified mRNA vaccination
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Pardi, N., M. J. Hogan, R. S. Pelc, H. Muramatsu, H. Andersen,
C. R. DeMaso, K. A. Dowd, et al. 2017. “Zika virus protection by a
single low dose nucleoside modified mRNA vaccination.” Nature 543
(7644): 248-251. doi:10.1038/nature21428. http://dx.doi.org/10.1038/
nature21428.
Published Version doi:10.1038/nature21428
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375205
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Zika virus protection by a single low dose nucleoside modified 
mRNA vaccination
Norbert Pardi1,*, Michael J. Hogan1,*, Rebecca S. Pelc2, Hiromi Muramatsu1, Hanne 
Andersen3, Christina R. DeMaso2, Kimberly A. Dowd2, Laura L. Sutherland4, Richard M. 
Scearce4, Robert Parks4, Wendeline Wagner3, Alex Granados3, Jack Greenhouse3, Michelle 
Walker3, Elinor Willis5, Jae-Sung Yu4, Charles E. McGee4, Gregory D. Sempowski4, Barbara 
L. Mui6, Ying K. Tam6, Yan-Jang Huang7, Dana Vanlandingham7, Veronica M. Holmes1, 
Harikrishnan Balachandran8, Sujata Sahu8, Michelle Lifton8, Stephen Higgs7, Scott E. 
Hensley5, Thomas D. Madden6, Michael J. Hope6, Katalin Karikó9, Sampa Santra8, Barney 
S. Graham10, Mark G. Lewis3, Theodore C. Pierson2, Barton F. Haynes4, and Drew 
Weissman1
1Department of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
2Viral Pathogenesis Section, National Institute of Allergy and Infectious Disease, National 
Institutes of Health, Bethesda, MD, 20892, USA
3Bioqual Inc., Rockville, MD, 20850-3220, USA
4Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA
5Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, PA, 19104, USA
6Acuitas Therapeutics, Vancouver, BC, V6T 1Z3, Canada
7Diagnostic Medicine and Pathobiology, College of Veterinary Medicine and the Biosecurity 
Research Institute, Kansas State University, Manhattan, KS, 66506, USA
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#termsReprints and 
permissions information is available at www.nature.com/reprints
Correspondence and requests for materials should be addressed to D.W. (dreww@upenn.edu).
*These authors contributed equally to this work
Author Contributions
N.P., M.J. Hogan, B.F.H, T.C.P., B.S.G, M.G.L., and D.W. designed the studies and evaluated data. N.P. and H.M. conducted mouse 
studies. M.J. Hogan performed virologic and immunologic assays for mouse and NHP studies. D.W., M.J. Hogan, N.P., and K.K. 
developed the mRNA construct and platform. E.W. and S.E.H. provided virologic technical assistance and reagents. V.H. provided 
molecular assay assistance. C.E.M., G.D.S., R.S.P., C.R.D., K.A.D., and T.C.P. conducted NAb assays. B.L.M., Y.K.T., T.D.M., and 
M.J. Hope developed and provided LNPs. Y.H., D.V., and S.H. provided NHP challenge stock. H.A., J.G., and M.W. conducted viral 
load analysis. M.G.L., L.L.S., R.M.S., W.W., and A.G. carried out the NHP immunization and challenge trial. M.J.B., J.Y., L.M., 
M.A.M., and S. Santra, H.B., S. Sahu, and M.L. processed NHP samples and conducted assays for NHP studies. N.P., M.J. Hogan, and 
D.W. wrote the paper with all co-authors.
Author Information
In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that 
Norbert Pardi, Michael J. Hogan, Katalin Karikó and Drew Weissman are named on patents that describe the use of nucleoside-
modified mRNA as a platform to deliver therapeutic proteins and vaccines. We have disclosed those interests fully to the University of 
Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents.
HHS Public Access
Author manuscript
Nature. Author manuscript; available in PMC 2017 August 02.
Published in final edited form as:
Nature. 2017 March 09; 543(7644): 248–251. doi:10.1038/nature21428.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
8Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard 
Medical School, Boston, MA, 02215 USA
9BioNTech RNA Pharmaceuticals, An der Goldgrube 12, 55131, Mainz, Germany
10Vaccine Research Center, National Institute of Allergy and Infectious Disease, National 
Institutes of Health, Bethesda, MD, 20892, USA
Abstract
Zika virus (ZIKV) has recently emerged as an explosive pandemic associated with severe 
neuropathology in newborns and adults1. There are no ZIKV-specific treatments or preventatives; 
thus, development of a safe and effective vaccine is a high priority. Messenger RNA (mRNA) has 
emerged as a versatile and highly effective platform to deliver vaccine antigens and therapeutic 
proteins2,3. Here, we demonstrate that a single low-dose intradermal immunization with lipid 
nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) encoding the pre-membrane 
and envelope (prM-E) glycoproteins of a 2013 ZIKV outbreak strain elicited potent and durable 
neutralizing antibody responses in mice and non-human primates. Immunization with 30 μg of 
nucleoside-modified ZIKV mRNA-LNPs protected mice from ZIKV challenges at 2 weeks or 5 
months post-vaccination, and a single dose of 50 μg was sufficient to protect non-human primates 
from a challenge at 5 weeks post-vaccination. These data demonstrate that nucleoside-modified 
mRNA-LNPs elicit rapid and durable protective immunity and thus represent a new and promising 
vaccine candidate for the global fight against ZIKV.
ZIKV, first identified in 19474, is a mosquito-borne and sexually transmitted flavivirus that 
has recently been associated with microcephaly and other birth defects in newborns and 
Guillain-Barré syndrome in adults1. Effective vaccines have been approved for other closely 
related flaviviruses5–7, but vaccine candidates for ZIKV have only recently been 
developed8–12. Multiple vaccine formats have been shown to protect mice or non-human 
primates (NHPs) from ZIKV infection, including plasmid DNA9–12, purified inactivated 
virus10,11, protein subunit8, and adenovirus vectors8,10. The ideal vaccine is safe and induces 
protective immunity after a single immunization, regardless of prior serologic history. Of the 
candidate Zika vaccines described to date, only a rhesus adenovirus platform (RhAd52) has 
been shown to confer protection after a single immunization in NHPs; however, the efficacy 
of the RhAd52 vector in humans is currently undefined. Additionally, pre-existing immunity 
to adenovirus serotypes can limit the efficacy of such vectors13,14, and low neutralizing titers 
to rhesus adenoviruses, including RhAd52, have been detected in humans15.
mRNA has emerged as a promising new vaccine modality that can elicit potent immune 
responses (reviewed in 2,3), while avoiding the safety risks and anti-vector immunity 
associated with some live virus vaccines (reviewed in 16). Vaccination with mRNA offers 
several advantages over other vaccine platforms: (I) it is a non-integrating, non-infectious 
gene vector that can be readily designed to express any protein with high efficiency, (II) it 
has the potential for cost-effective and highly scalable manufacturing, and (III) small doses 
are sufficient to induce protective immune responses.
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Here, we designed a novel, potent anti-ZIKV vaccine in which the prM-E glycoproteins of 
ZIKV H/PF/201317 are encoded by mRNA (Extended Data Fig. 1a) containing the modified 
nucleoside 1-methylpseudouridine (m1ψ), which prevents innate immune sensing and 
increases mRNA translation in vivo18. Nucleoside-modified ZIKV prM-E mRNA was 
formulated for vaccination in lipid nanoparticles (LNPs), which have been shown to mediate 
efficient and prolonged protein expression by mRNA in vivo19. Studies of ZIKV and other 
flaviviruses have demonstrated that co-expression of prM and E proteins is sufficient to 
assemble and secrete subviral particles12,20. ZIKV prM-E-encoding mRNA was first 
characterized by transfecting HEK 293T cells and human and murine dendritic cells (DCs). 
ZIKV E protein was produced by all cell types and was secreted into the supernatant of 
293T cells (Extended Data Fig. 1b). We hypothesize that DCs also secrete E protein and that 
it is rapidly endocytosed, as has been proposed for HIV gag21. E protein in supernatant was 
pelleted by ultracentrifugation when incubated with PBS, but not with 0.5% Triton X-100, 
consistent with subviral particle production from prM-E mRNA20 (Extended Data Fig. 1c).
The immune response induced by the nucleoside-modified ZIKV prM-E mRNA-LNP 
vaccine was first evaluated in C57BL/6 mice. Animals were intradermally (i.d.) immunized 
with 30 μg of ZIKV prM-E mRNA-LNPs or poly(C) RNA-LNPs (negative control). No 
inflammation or other adverse events were observed at the sites of injection. Polyfunctional 
E protein-specific CD4+ T cell responses were detected based on intracellular IFN-γ, TNF-
α, and IL-2 production by ZIKV E protein-stimulated splenocytes at week 2 post-
vaccination (Fig. 1a and Extended Data Fig. 2). ZIKV E-specific serum IgG developed 
quickly in vaccinated mice and stabilized at an endpoint titer of 180,000 (~90 μg/ml) at 
weeks 8 to 12 (Fig. 1b and Extended Data Fig. 3a). Anti-ZIKV neutralizing antibodies 
(NAb) were measured using two independent assays: a standard plaque reduction 
neutralization test (PRNT) and a ZIKV reporter viral particle (RVP) assay12. The mean 
PRNT50 titer against ZIKV MR-766 peaked at ~1,300 at week 8 (Fig. 1c) and was relatively 
stable until week 12. The mean RVP NAb titer (EC50) against ZIKV H/PF/2013 reached 
~105 at weeks 8 and 12 (Fig. 1d). The detection of higher NAb titers in the RVP assay 
compared to other assay formats similar to PRNT has been previously reported12. In 
addition, we noted that the ratio of RVP to PRNT titers was not fixed and varies with the 
animal model and viral isolate.
Immunogenicity of the nucleoside-modified ZIKV prM-E mRNA-LNP vaccine was next 
evaluated in BALB/c mice. E-specific serum IgG peaked at week 8 and remained stable 
between weeks 8 and 20 (endpoint titers ~200,000; 90–130 μg/ml) (Fig. 1e and Extended 
Data Fig. 3b). PRNT50 NAb increased to a maximum of ~1,100 at week 16 and remained 
stable until week 20 (Fig. 1f). The RVP NAb titer rose to 50,000 at week 8 and remained 
above 20,000 until week 20 (Fig. 1g).
A challenge study was conducted in BALB/c mice immunized i.d. with 30 μg of nucleoside-
modified ZIKV prM-E mRNA-LNPs or poly(C) RNA-LNPs. Mice were intravenously (i.v.) 
challenged at week 2 (short-term) or week 20 (long-term) post-immunization with 200 
plaque-forming units (PFU) of ZIKV PRVABC59. In the short-term protection study, 8 of 9 
control mice developed viremia by day 3, with a median peak of ~14,000 copies/ml. All 
ZIKV mRNA-immunized mice (n=9) were protected from detectable viremia (Fig. 2a). In 
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the long-term study, all control mice (n=5) showed viremia on day 3, with a median peak of 
1,200 copies/ml, while none of the ZIKV mRNA-immunized mice (n=10) had detectable 
viremia at days 3 or 7 (Fig. 2b). These data demonstrate that a single immunization with 
nucleoside-modified ZIKV prM-E mRNA-LNPs rapidly elicits durable protection from 
detectable viremia with a heterologous ZIKV strain in mice.
We next evaluated the efficacy of the nucleoside-modified ZIKV mRNA-LNP vaccine in 
rhesus macaques (Macaca mulatta), a non-human primate species that recapitulates several 
features of ZIKV infection in humans22. Macaques were immunized i.d. with doses of 600 
μg, 200 μg or 50 μg of nucleoside-modified ZIKV prM-E mRNA-LNPs. As in mice, no 
inflammation or other adverse events were observed. E-specific binding IgG and NAb were 
efficiently induced by all three vaccine doses, with no statistically significant differences 
between groups. Endpoint IgG titers rose to >300,000 in all groups at week 4 and were 
maintained at ≥100,000 until week 12 (Fig. 3a). PRNT50 NAb titers against MR-766 peaked 
at ~400 at week 2 (Extended Data Fig. 4a). To facilitate comparison of NAb titers across 
laboratories, the neutralization curve is shown for a human ZIKV-neutralizing mAb, A3594, 
in the PRNT assay (Extended Data Fig. 5). NAb titers obtained with a focus reduction 
neutralization test (FRNT), which has a format similar to PRNT, were stable around 400 
against ZIKV MEX I-44 at weeks 2 through 12 (Fig. 3b). The RVP assay revealed NAb 
titers against H/PF/2013 of ~10,000 at week 2 and ~17,000 at week 4 (Fig. 3c), and a titer of 
~3,000 against MR-766 at week 4 (Extended Data Fig. 4b). The neutralization of both 
Asian- and African-lineage viruses is consistent with a prior report demonstrating the 
existence of only one serotype of ZIKV23. The absence of a significant dose-dependent 
effect on the antibody response in any assay (Kruskal-Wallis test, p>0.05) suggests that a 
low dose of 50 μg (approximately 0.02 mg/kg) was sufficient, or possibly more than 
sufficient, to induce robust anti-ZIKV immunity in macaques.
Rhesus macaques were challenged at week 5 by subcutaneously (s.c.) injecting 104 TCID50 
of ZIKV PRVABC59 into five vaccinated animals and six control animals (Extended Data 
Table 1). All control animals became infected with median peak plasma viremia of 7,000 
ZIKV RNA copies/ml (Fig. 4). In contrast, vaccinated macaques were highly protected from 
ZIKV infection. Four of five animals — including three that received the lowest dose of 50 
μg and one that received the medium dose of 200 μg — had no detectable viremia (<50 
copies/ml) at all time points. We detected a low and transient viral blip of 100 copies/ml at 
day 3 post-challenge in one animal that received the highest dose of 600 μg of ZIKV prM-E 
mRNA-LNPs, representing a ~99% reduction in peak viremia compared to the control 
animals. This animal exhibited among the lowest NAb titers in multiple assays at week 4 
post-vaccination: PRNT50 of 36 to MR-766, FRNT50 of 226 to MEX I-44, and RVP titers of 
986 to MR-766 and 5,812 to H/PF/2013 (Fig. 3 and Extended Data Fig. 4). The significance 
of a low-level viral blip in one animal, including implications for a correlate of protection, 
are as yet uncertain and warrant further study with a greater number of animals.
In this report, we demonstrate that a single, low-dose i.d. immunization with nucleoside-
modified ZIKV prM-E mRNA-LNPs is protective in both mice and rhesus macaques and 
elicits higher NAb responses than a single immunization of multiple recently reported ZIKV 
vaccine candidates, including purified inactivated virus (PIV) and plasmid DNA vaccines 
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encoding prM-E or M-E10–12. In mice, PRNT50 NAb increased steadily over several months, 
rising to levels 50–100 times higher than those induced by a single immunization with PIV 
or DNA vaccines11,12. The ZIKV mRNA-LNP vaccine conferred complete, rapid, and 
durable protection in mice that was maintained for at least 5 months, and likely much longer, 
since NAb titers were stable. The mouse challenge studies also revealed that ZIKV 
PRVABC59 replicated more efficiently (p=0.02, Mann-Whitney test) in 8 week-old BALB/c 
mice compared to 25 week-old mice, when two identical aliquots and doses of challenge 
virus stock were used. A prior report has shown that ZIKV-related mortality in immune-
competent mice decreases between 1 and 4 weeks of age24, but ZIKV replication in adult 
mice has not yet been well described.
In rhesus macaques, a single immunization with 50 μg ZIKV prM-E mRNA-LNPs induced 
RVP NAb titers that were 50 times higher than those induced by one immunization of 1 mg 
DNA vaccine and over 2 times higher than those induced by two immunizations of DNA12, 
as measured by the same assay in the same laboratory. ZIKV mRNA-LNP NAb titers may 
overlap with those elicited by one injection of PIV or RhAd52 ZIKV vaccines in macaques, 
although differing assay formats prevent a precise comparison. The FRNT NAb titers 
elicited by ZIKV mRNA-LNP in macaques were maintained at a stable level until 12 weeks 
post-immunization, suggesting that protection may be durable.
Future studies on the nucleoside-modified ZIKV mRNA-LNP vaccine will allow us to 
explore the impact of a boost, study the effect of this vaccine on other flavivirus infections, 
and determine efficacy in preventing fetal ZIKV infection and disease.
Ethics statement
Animals
The investigators faithfully adhered to the “Guide for the Care and Use of Laboratory 
Animals” by the Committee on Care of Laboratory Animal Resources Commission on Life 
Sciences, National Research Council. Mouse studies were conducted under protocols 
approved by the University of Pennsylvania (UPenn) IACUCs. Rhesus macaques (Macaca 
mulatta) were housed at BIOQUAL Inc. (Rockville, MD). Macaque experiments were 
reviewed and approved by BIOQUAL and UPenn Animal Care and Use Committees. All 
animals were housed and cared for according to local, state and federal policies in an 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC)-accredited facility.
Human cells
Research involving human cells complied with the Declaration of Helsinki. De-identified 
leukapheresis cells were obtained from the UPenn Immunology Core under their 
Institutional Review Board (IRB) approved protocol, and were deemed exempt by the 
UPenn IRB.
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Antibody reagents
The pan-flavivirus murine monoclonal antibody 4G2, clone D1-4G2-4-15 (EMD Millipore 
MAB10216) was used to detect ZIKV E protein by Western blot. The following antibodies 
were used for flow cytometry: anti-CD4 PerCP/Cy5.5 (Clone GK1.5, Biolegend), anti-CD3 
APC-Cy7 (Clone 145-2C11, BD Biosciences), anti-CD27 PE (Clone LG.3A10, BD 
Biosciences), anti-TNF-α PE-Cy7 (Clone MP6-XT22, BD Biosciences), anti-IFN-γ AF700 
(Clone XMG1.2, BD Biosciences), anti-IL-2 APC (Clone JES6-5H4, BD Biosciences). 
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Life Technologies) was used to 
discriminate dead cells and debris. The following antibodies were used for ELISA assays: 
goat anti-mouse IgG HRP (Sigma 4416), goat anti-monkey IgG HRP (Sigma 2054), and 
ZIKV E protein-binding mAb NR-4747 clone E19 (BEI Resources). ZIKV-neutralizing 
human monoclonal antibody Ab3594 was provided by the Duke University, Duke-NUS 
Graduate Medical School, National University of Singapore team of Charles McGee, 
Gregory D. Sempowski, Robert Parks, Eng Eong Ooi, Barton F. Haynes, M. Anthony 
Moody, Sheemei Lok, and Hua-Xin Liao.
Protein reagents
Purified recombinant ZIKV E protein (Aalto Bioreagents AZ 6312) was used in ELISAs to 
detect E protein-specific IgG, in Western blots as a positive control and in mouse splenocyte 
stimulation.
mRNA production
mRNA was produced as previously described25 using T7 RNA polymerase on linearized 
plasmid (pTEV-ZIKVprM-E-A101) encoding codon-optimized26 ZIKV strain H/PF/2013 
(Asian lineage, French Polynesia, 2013, GenBank: KJ776791) prM-E glycoproteins. mRNA 
was transcribed to contain 101 nucleotide-long poly(A) tails. 1-methylpseudouridine-5′-
triphosphate (TriLink) instead of UTP was used to generate modified nucleoside-containing 
mRNA. mRNA was capped using the m7G capping kit with 2′-O-methyltransferase to 
obtain cap1 and was purified by a fast protein liquid chromatography (FPLC) method, as 
described27. mRNA was analyzed by agarose gel electrophoresis and stored frozen at 
−20°C.
Cell culture
Human embryonic kidney (HEK) 293T cells (ATCC) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 2 mM L–glutamine (Life Technologies) and 
10% fetal calf serum (FCS) (HyClone) (complete medium). The 293T cell line was tested 
for mycoplasma contamination after receipt from ATCC and before expansion and 
cryopreservation. Human dendritic cells (huDCs) were generated from monocytes, as 
described28, and grown in RPMI 1640 medium containing 2 mM L–glutamine (Life 
Technologies) and 10% fetal calf serum (FCS) (HyClone) (complete medium) supplemented 
with 50 μg/ml recombinant human GM-CSF and 100 μg/ml recombinant human IL-4 (R&D 
systems). Cells were maintained by adding fresh medium containing IL-4 and GM-CSF 
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every 3 days and used on day 7. Murine dendritic cells (muDCs) were generated from bone 
marrow cells obtained from the femurs of animals and grown in complete medium 
supplemented with 50 μg/ml murine GM-CSF (R&D systems). Cells were maintained by 
adding fresh medium containing murine GM-CSF every 3 days and used on day 7.
mRNA transfection
Transfection of human and murine DCs and HEK 293T cells was performed with TransIT-
mRNA (Mirus Bio) according to the manufacturer instructions: mRNA (0.3 μg) was 
combined with TransIT-mRNA Reagent (0.34 μl) and Boost Reagent (0.22 μl) in 17 μl of 
serum free medium, and the complex was added to 2 × 105 cells in 183 μl complete medium. 
Supernatant was collected and cells were lysed for 1 hr on ice in RIPA buffer (Sigma) at 18 
hr post-transfection.
Western blot analysis of E protein expression
Whole cell lysates and supernatants from ZIKV prM-E transfected cells were assayed for 
ZIKV E protein by non-denaturing SDS-PAGE Western blot. Samples were combined with 
4× Laemmli buffer (Bio-Rad) and separated on a 4–15% precast polyacrylamide Criterion 
TGX gel (Bio-Rad) for 45 min at 200 V. Transfer to PVDF membrane was performed using 
a semi-dry apparatus (Ellard Instrumentation, Ltd.) at 10 V for 1 hr. The membrane was 
blocked with 5% non-fat dry milk in TBS buffer containing 0.5% Tween-20. E protein was 
detected using 1:10,000 4G2 ascites for 1 hr, followed by secondary goat anti-mouse IgG 
HRP 1:10,000 for 1 hr. Antibody incubations were performed at room temperature in 
blocking buffer. Blots were developed using Luminata Forte substrate (Millipore) and a 
Kodak X-OMAT 1000A processor.
Characterization of E protein in supernatant
Supernatant from HEK 293T cells transfected with ZIKV prM-E mRNA was tested for 
whether E protein could be pelleted and disrupted with detergent, consistent with subviral 
particles. Supernatant was incubated in PBS alone or PBS with 0.5% Triton X-100 for 1 hr 
on ice. Samples were then spun at 42,000 rpm for 2.5 hr in a Beckman TLA-55 rotor. The 
supernatant was then removed from the pellet, which was resuspended in 50 μl of PBS. 
Equal volumes of the input, pellet, and post-centrifugation supernatant fractions were then 
analyzed by Western blot, as described above.
Lipid nanoparticle (LNP) formulation of the mRNA
FPLC-purified mRNAs and polycytidylic acid (poly(C) RNA) (Sigma) were encapsulated in 
LNPs using a self-assembly process in which an aqueous solution of mRNA at pH 4.0 is 
rapidly mixed with a solution of lipids dissolved in ethanol29. LNPs used in this study were 
similar in composition to those described previously29,30, which contain an ionizable 
cationic lipid (proprietary to Acuitas)/phosphatidylcholine/cholesterol/PEG-lipid 
(50:10:38.5:1.5 mol/mol) and were encapsulated at an RNA to total lipid ratio of ~0.05 (wt/
wt). They had a diameter of ~80 nm as measured by dynamic light scattering using a 
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Zetasizer Nano ZS instrument (Malvern Instruments Ltd, Malvern, UK). RNA-LNP 
formulations were stored at −80°C at a concentration of RNA of ~1 μg/μl.
Administration of LNPs to mice and rhesus monkeys
Mice
Female BALB/c and C57BL/6 mice aged 8 weeks were purchased from Charles River 
Laboratories. mRNA-LNPs were diluted in PBS and injected into animals intradermally 
with a 3/10cc 29½G insulin syringe (BD Biosciences). Four sites of injection (30 μl each) 
over the lower back were used.
Monkeys
Ketamine anesthetized animals were shaved on their back and injected with mRNA-LNPs 
diluted in PBS. Ten sites of injection (60 μl each) were used. Animals of similar age and 
weight were randomly designated to dose groups.
Blood collection from mice and rhesus macaques
Mice
Blood was collected from the orbital sinus under isoflurane anesthesia. Blood was 
centrifuged for 10 min at 13,000 rpm and the serum was stored at −20°C and used for 
ELISA and virus neutralization assays. EDTA-plasma was collected to isolate RNA for qRT-
PCR analysis.
Monkeys
Blood was collected by femoral venipuncture under ketamine anesthesia, and serum and 
EDTA-plasma were collected and stored at −80°C for ELISA, neutralization analysis, and to 
isolate RNA for qRT-PCR.
Stimulation and staining of splenocytes
Single cell suspensions from spleens were made in complete medium. Splenocytes were 
washed once in PBS and resuspended in complete medium at 2 × 107 cells/ml. 2 × 106 cells 
(100 μl) per sample were stimulated for 6 hr at 37°C using 2 μg/ml purified recombinant 
ZIKV E protein. Golgi Plug (brefeldin A, BD Biosciences) and Golgi Stop (monensin, BD 
Biosciences) were diluted 1:100 and 1:143 in complete medium, respectively, and 20 μl from 
both diluted reagents were added to each sample to inhibit the secretion of intracellular 
cytokines after 1 h. An unstimulated sample for each animal was included. PMA (10 ng/ml)-
ionomycin (250 ng/ml) (Sigma) stimulated samples were used as positive controls.
After stimulation, cells were washed in PBS and stained using the LIVE/DEAD Fixable 
Aqua Dead Cell Stain Kit (Life Technologies) and then surface stained for CD4 and CD27. 
Antibodies were incubated with cells for 30 min at RT. Following surface staining, cells 
were washed in FACS buffer and fixed using the Cytofix/Cytoperm kit (BD Biosciences) 
according to the manufacturer’s instructions. Following fixation, the cells were washed in 
the appropriate perm buffer and incubated with antibodies against CD3, TNF-α, IFN-γ and 
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IL-2 for 1 hr at RT. Following staining, the cells were washed with the appropriate perm 
buffer, fixed (PBS containing 1% paraformaldehyde) and stored at 4°C until analysis.
Flow cytometry
Splenocytes were analyzed on a modified LSR II flow cytometer (BD Biosciences). One 
hundred thousand events were collected per specimen. After the gates for each function were 
created, the Boolean gate platform was used to create the full array of possible 
combinations, equating to seven response patterns when testing three functions. Data were 
expressed by subtracting the percentages from the unstimulated stained cells from the E 
protein stimulated stained cells.
Enzyme-linked immunosorbent assays (ELISA) for ZIKV E-specific IgG
Immulon 4HXB ELISA plates were coated with 6 μg/ml purified recombinant ZIKV E 
protein in 0.1 M sodium bicarbonate buffer overnight at 4°C. The plate was blocked with 2% 
BSA in PBS for 1 hr, and washed three times with wash buffer (PBS with 0.05% Tween-20). 
Mouse or rhesus macaque sera were diluted in blocking buffer and incubated on the plate for 
1 hr at room temperature, followed by four washes. Secondary antibody HRP conjugate was 
diluted 1:10,000 in blocking buffer and incubated on the plate for 1 hr, followed by four 
washes. TMB substrate (KPL) was applied to the plate and the reaction was stopped with 2 
N sulfuric acid. The absorbance was measured at 450 nm using an MRX Revelation 
microplate reader. ZIKV E-specific IgG was expressed in two ways: as an endpoint dilution 
titer, defined as the highest reciprocal dilution of serum to give an OD greater than the sum 
of the background OD plus 0.01 units; and as an estimate of the absolute IgG concentration, 
which was based on the murine mAb NR-4747 as a standard (applicable only to mouse 
samples). All samples were run at least in technical duplicates.
ZIKV MR-766 plaque reduction neutralization tests (PRNT)
ZIKV strain MR-766 (African lineage, Uganda, 1947, GenBank: AY632535) (UTMB 
Arbovirus Reference Collection) was produced in Vero cells (ATCC CCL-81) and 50 plaque 
forming units were incubated with increasing dilutions of heat-inactivated sera in serum-free 
DMEM (Corning) medium for 1 hr at 37°C. The virus/serum mixture (200 μl) was added to 
a confluent monolayer of Vero cells in 6-well format and incubated for 1.5 hr at 37°C with 
intermittent rocking. Then, 3 ml of overlay, containing a final concentration of 0.5% 
methylcellulose (4,000 centipoise) (Sigma), 1X DMEM (Gibco), 16 mM HEPES, 0.56% 
sodium bicarbonate, 1.6X GlutaMAX (Gibco), 1X penicillin/streptomycin (Corning), and 4 
μg/ml amphotericin B (Gibco), was added to each well, and plates were incubated for 5 days 
at 37°C in 5% CO2. The overlay was aspirated and cells were fixed and stained with 0.5% 
crystal violet (Sigma) in 25% methanol, 75% deionized water. Wells were rinsed with 
deionized water to visualize plaques. Neutralization titers (EC50) were determined by 
plotting a line through the linear portion of the curve that crossed 50% inhibition and 
calculating the reciprocal dilution of sera required for 50% neutralization of infection. EC50 
titers below the limit of detection are reported as half of the limit of detection.
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ZIKV MEX I-44 focus reduction neutralization tests (FRNT)
ZIKV MEX I-44 (Asian lineage, Mexico, 2016, GenBank: KX856011) stocks were 
generated via propagation in Vero 76 cells (ATCC CRL-1587) and harvested as clarified cell 
culture lysate/supernatant. Stock titers were quantified via standard focus forming assay. 
FRNT was performed by combining a standard dose of ZIKV with two-fold serial dilutions 
of heat-inactivated serum for one hour at 37°C. Virus-serum mixtures (100 μl) were then 
inoculated onto Vero 76 monolayers, incubated at 37°C for 1 hr and overlayed with an 
Avicel (FMC Biopolymer)-containing growth medium. After 3 days of incubation, plates 
were formalin-fixed, permeabilized, blocked, and stained via sequential incubation with 
biotin-conjugated 4G2 mAb (ATCC HB-112), streptavidin-HRP (BD Biosciences) and 
TrueBlue Peroxidase Substrate (KPL). Virus input was verified in parallel (acceptable range: 
20–60 foci). FRNT50 (EC50 titers) are reported as the highest reciprocal dilution giving a 
focus count ≤ the 50% neutralization cutoff, and the geometric mean was computed for 
technical duplicates.
Reporter virus particle (RVP) production
Pseudo-infectious RVPs were produced by complementation of a GFP-expressing WNV 
sub-genomic replicon23,31 with a plasmid encoding the viral structural proteins (capsid-prM-
E). Briefly, ZIKV MR-766 and ZIKV H/PF/2013 RVPs were produced via co-transfection of 
HEK-293T cells with the structural gene and replicon plasmids (3:1 ratio by mass) using 
Lipofectamine 3000 per the manufacturer’s protocol (Invitrogen). Transfected cells were 
incubated at 30°C and RVP-containing supernatants harvested on days 3–6. Stocks were 
passed through a 0.2 μm filter and aliquots stored at −80°C until use. Stock titers were 
determined by infecting Raji-DCSIGNR cells with serial dilutions of filtered RVP 
supernatants. GFP-positive cells were assessed by flow cytometry at 48 hr post-infection and 
RVP titers calculated.
RVP neutralization assay
Previously titered RVPs were diluted to ensure antibody excess at informative points on the 
dose-response curves and incubated with serial dilutions of mouse or macaque sera for 1 hr 
at 37°C to allow for steady-state binding. Raji-DCSIGNR cells were then infected with 
antibody-RVP complexes in duplicate technical replicates. Infections were carried out at 
37°C and GFP-positive infected cells detected by flow cytometry 24–48 hr later. 
Neutralization results were analyzed by non-linear regression to estimate the reciprocal 
dilution of sera required for half-maximal neutralization of infection (EC50 titer) (Prism 6, 
GraphPad). The initial dilution of sera (based on the final volume of RVPs, cells, and sera) 
was set as the limit of confidence of the assay. Titers for which non-linear regression was 
predicted to be below this threshold were reported as a titer half the limit of confidence. 
Individual EC50 titers are reported as the geometric mean of technical replicates.
Pardi et al. Page 10
Nature. Author manuscript; available in PMC 2017 August 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Preparation of challenge ZIKV virus
Mice
Challenge ZIKV strain PRVABC59 (Asian lineage, Puerto Rico, 2015, GenBank: 
KU501215) (BEI Resources NR-50240) was grown in Vero CCL81 cells. A T175 flask of 
cells at 75–90% confluency was inoculated with an MOI of 0.01 ZIKV in 10 ml of serum-
free DMEM medium. The flask was incubated at 37°C, 5% CO2 for 1.5 hr with intermittent 
gentle rocking, then warmed media was added to a final concentration of 1.5% FBS, 1X 
GlutaMAX (Gibco) and 1X penicillin/streptomycin (Corning) in a final volume of 25 ml. 
The flask was incubated for 4 days or until cytopathic effects were visible. Then supernatant 
was collected and ultra-centrifuged at 20,000 rpm for 1 hr at 4°C in a Sorvall SureSpin 630 
rotor. The supernatant was removed and the pellet was resuspended in 1 ml of serum-free 
DMEM, aliquoted, and stored at −80°C. Before challenge, virus was thawed and diluted in 
PBS to 2,000 PFU/ml.
Monkeys
Challenge ZIKV strain PRVABC59 was grown in Vero 76 CRL-1587 cells. T150 flasks of 
cells at 80–85% confluency were used for propagation. Infection was performed with 100 μl 
stock virus diluted in 4 ml of fresh L-15 media (Gibco) supplemented with 10% fetal bovine 
serum (Gibco), 10% tryptose phosphate broth (Sigma Aldrich), 1X penicillin/streptomycin 
(Gibco) and L-glutamine (Gibco) and adsorbed for 1 hr at room temperature with gentle 
agitation every 15 min. Each flask received 7 ml of fresh L-15 media after adsorption and 
was incubated for 4 days at 37°C. Cellular debris was removed by centrifugation at 1,200 
rpm for 5 min at 4°C in an Eppendorf A-4-62 rotor. Virus stocks were aliquoted and stored 
at −80°C.
Zika virus challenge in mice and rhesus macaques
Mice
Two or 20 weeks after vaccination, mice were bled and then challenged intravenously with 
200 PFU of ZIKV-PR (PRVABC59) in 100 μl of PBS. Blood was collected 3 and 7 days 
post-challenge to determine viral loads (ZIKV RNA copies/ml) in plasma.
Monkeys
Macaques were anesthetized with ketamine and injected subcutaneously in the hind thigh 
with 104 TCID50 of ZIKV-PR in a volume of 1 ml in PBS. Blood was collected 1, 3, 5, and 7 
days post-challenge to determine viral loads (ZIKV RNA copies/ml) in plasma.
Viral load quantification (qRT-PCR)
Using blinded samples, RNA was isolated from 200 μl (macaque) or 50 μl (mouse) plasma 
using the QIAamp MinElute Virus spin kit (Qiagen). Extracted RNA was used for 
amplification using the SensiFAST Probe Lo-ROX One-Step Kit (Bioline BIO-78005) on a 
7500 Real-Time PCR system (Applied Biosystems). Primers and probe were designed to 
amplify a conserved region of the capsid gene from ZIKV BeH815744, as follows: Fwd: 
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5′GGAAAAAAGAGGCTATGGAAATAATAAAG; Rev: 
5′CTCCTTCCTAGCATTGATTATTCTCA; probe: 5′AGTTCAAGAAAGATCTGGCTG.
Primers and probe were used at a final concentration of 2 μM, and the following program 
was run: 48°C for 30 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 1 
min at 60°C. Assay sensitivity was 50 copies/ml for macaque and 200 copies/ml for mouse 
samples.
Statistical analysis
GraphPad Prism 5.0f was used to perform Mann-Whitney and Kruskal-Wallis (with Dunn’s 
correction) tests to compare immune responses in vaccinated and control mice and in 
different dose groups of macaques, respectively. SPICE 5.35 and Microsoft Excel software 
was used to perform Student’s t tests to compare T cell responses in vaccinated and control 
mice.
Data availability
All data and full plasmid sequences are available by request of the corresponding author.
Extended Data
Extended Data Figure 1. Design and characterization of ZIKV prM-E mRNA
(a) The ZIKV mRNA encodes the signal peptide (SP) from MHC class II and prM and E 
glycoproteins from ZIKV H/PF/2013. (b) mRNA was transfected into 293T cells (n=3), 
human DC (n=3), or murine DC (n=2). E protein expression in cell lysate and supernatant 
was probed by Western blot, using firefly luciferase-encoding mRNA-transfected cells as a 
negative control. (c) ZIKV mRNA supernatant from transfected 293T cells was 
characterized by ultracentrifugation in the presence and absence of 0.5% Triton X-100, 
followed by Western blot of input (IN), pellet (P), and final supernatant (S) fractions (n=3).
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Extended Data Figure 2. Nucleoside-modified ZIKV mRNA-LNP immunization elicits 
polyfunctional ZIKV E-specific CD4+ T cell responses
C57BL/6 mice were immunized with 30 μg of nucleoside-modified ZIKV prM-E mRNA-
LNPs (n=8) or control poly(C) RNA-LNPs (n=4). At week 2, antigen-specific CD4+ T cells 
were detected by intracellular cytokine staining. Bar graph shows mean frequencies of 
combinations of cytokines produced by CD4+ T cells. Error bars indicate the SEM, and 
asterisk indicates a significant difference (p<0.05) by Student’s t-test.
Extended Data Figure 3. ZIKV E-specific IgG concentration in mice
Sera from (a) C57BL/6 mice (n=4 control; n=8 ZIKV mRNA-LNP) or (b) BALB/c mice 
(n=5 control; n=10 ZIKV mRNA-LNP) were assayed by ELISA, and estimates of ZIKV E-
specific IgG concentrations were calculated using murine mAb NR-4747 as a standard. 
Points represent individual mice; horizontal lines indicate the mean. Responses in vaccine 
and control groups were compared at each time point by Mann-Whitney test: p<0.01 for all 
comparisons.
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Extended Data Figure 4. Neutralizing antibody responses against ZIKV MR-766 in macaques 
immunized with ZIKV prM-E mRNA-LNPs
Sera from immunized macaques were evaluated for neutralization of ZIKV MR-766 using 
(a) the PRNT assay or (b) the RVP assay at the indicated time points. Shaded area indicates 
values below the limit of detection and horizontal bars indicate the mean. Immune responses 
in dose groups were compared by Kruskal-Wallis test: p>0.05 for all comparisons.
Extended Data Figure 5. Neutralization curve for a human anti-ZIKV neutralizing mAb
ZIKV MR-766 was neutralized by Ab3594, a human ZIKV-neutralizing monoclonal 
antibody, as a positive control in the PRNT assay. Shown is a representative curve (n=4). 
Mean EC50 = 0.026 μg/ml, SD=5.4.
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Extended Data Table 1
Characteristics of rhesus macaques in vaccination and 
challenge experiments
Asterisk indicates the animals that were challenged with ZIKV.
Immunization Group ID Weight (kg) Sex DOB
ZIKV prM-E mRNA-LNP, 600 μg 1
6858 3.3 M 5/19/14
150250 3.05 F 3/22/15
150793 2.55 M 4/1/15
150796* 2.75 F 4/13/15
ZIKV prM-E mRNA-LNP, 200 μg 2
150251 2.95 M 3/22/15
150795 2.55 M 4/12/15
150798* 2.35 F 4/26/15
ZIKV prM-E mRNA-LNP, 50 μg 3
6857* 3.15 F 6/6/14
150252* 2.15 F 3/25/15
150794* 2.75 M 4/5/15
Challenge control group (unimmunized) 4
6143* 7.85 F 7/3/09
6154* 8.95 F 4/6/10
6076* 7.6 M 10/20/11
6150* 11.55 M 1/26/10
6211 * 8.65 M 5/2/10
6157* 10.15 F 4/3/10
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Figure 1. Nucleoside-modified ZIKV mRNA-LNP immunization elicits ZIKV-specific T helper 
and neutralizing antibody responses
a–d, C57BL/6 mice were immunized i.d. with 30 μg of nucleoside-modified ZIKV prM-E 
mRNA-LNPs (n=8) or control poly(C) RNA-LNPs (n=4). (a) At week 2, splenic antigen-
specific CD4+ T cells were detected by intracellular cytokine staining. The antibody 
response was monitored by (b) ELISA, (c) PRNT using ZIKV MR-766, and (d) RVP using 
ZIKV H/PF/2013. e–g, BALB/c mice were immunized similarly with ZIKV mRNA-LNPs 
(n=10) or poly(C) RNA-LNPs (n=5) and monitored by (e) ELISA, (f) PRNT using MR-766, 
and (g) RVP using H/PF/2013. Points represent individual mice; horizontal lines show the 
mean; shaded area indicates values below the limit of detection. The controls in d and g are 
from the week 8 time point. Asterisk indicates p<0.05 in unpaired t-test; antibody responses 
in vaccine and control groups were compared at each time point by Mann-Whitney test: 
p<0.01 for all comparisons.
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Figure 2. A single immunization of nucleoside-modified ZIKV prM-E mRNA-LNPs provides 
rapid and durable protection from ZIKV challenge in mice
BALB/c mice immunized i.d. with 30 μg of ZIKV prM-E mRNA-LNPs or control poly(C) 
RNA-LNPs were challenged i.v. with 200 PFU ZIKV PRVABC59 at (a) 2 weeks (n=9 per 
group) or (b) 20 weeks (n=5 control mice; n=10 ZIKV mRNA-LNP mice) post-vaccination, 
and plasma viral loads were measured by qRT-PCR for ZIKV capsid RNA. ‡ symbol 
indicates two overlapping curves. Shaded area indicates values below the limit of detection 
(200 copies/ml), with undetectable curves staggered to show individual mice. Day 3 viremia 
in vaccine and control groups was compared by Mann-Whitney test: p<0.001 for both 
challenges.
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Figure 3. Nucleoside-modified ZIKV mRNA-LNP immunization elicits potent ZIKV-specific 
neutralizing antibody responses in non-human primates
Rhesus macaques were immunized with 600 μg (n=4), 200 μg (n=3), or 50 μg (n=3) of 
ZIKV prM-E mRNA-LNPs, and the antibody response was quantified by (a) ELISA, (b) 
FRNT using ZIKV MEX I-44, and (c) RVP using ZIKV H/PF/2013. Pre-challenge (weeks 0 
to 4) and unchallenged animal data are shown. Points represent individual monkeys; shaded 
area indicates values below the limit of detection; horizontal lines indicate the mean. 
Immune responses in dose groups were compared by Kruskal-Wallis test: p>0.05 for all 
comparisons.
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Figure 4. A single immunization of nucleoside-modified ZIKV prM-E mRNA-LNPs protects 
rhesus macaques from ZIKV challenge at 5 weeks post-immunization
Six unvaccinated control macaques and five vaccinated macaques that received 50 μg (n=3), 
200 μg (n=1), or 600 μg (n=1) of ZIKV mRNA-LNPs at week 0 were challenged s.c. with 
104 TCID50 of ZIKV PRVABC59 at week 5. Viral loads were measured in plasma by qRT-
PCR for ZIKV capsid RNA. Shaded area indicates values below the limit of detection (50 
copies/ml), and undetectable values were staggered to show individual animals. Day 3 and 5 
viremia in vaccine and control groups was compared by Mann-Whitney test: p<0.001.
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